You are here

  • Home
  • Online First
  • Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes

Article Text

Article menu

other Versions

Download PDFPDF
Therapeutics
Randomised controlled trial
Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes
  1. Klaus K A Witte,
  2. Haqeel A Jamil
  1. Division of Cardiovascular and Diabetes Research, University of Leeds, Leeds, West Yorkshire, UK
  1. Correspondence to: Klaus K A Witte Division of Cardiovascular and Diabetes Research, LIGHT laboratories, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; k.k.witte{at}leeds.ac.uk

https://doi.org/10.1136/eb-2012-100877

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Homma S, Thompson JL, Pullicino PM, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69.OpenUrlCrossRefPubMedWeb of Science

    Context

    Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear.

    Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, aspirin 300 mg daily, placebo),2 Heart failurE Long-term Antithrombotic Study (aspirin 325 mg daily or warfarin for patients with ischaemic heart disease (IHD) or warfarin or placebo in the non-ischaemics)3 and Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH: warfarin, clopidogrel 75 mg daily, …

    View Full Text

    Footnotes

    • Competing interests None.